ISEE IVERIC bio Inc.

1.14
+0.03  (+2%)
Previous Close 1.11
Open 1.11
Price To Book 0.46
Market Cap 47,076,872
Shares 41,477,420
Volume 24,528
Short Ratio
Av. Daily Volume 82,538

NewsSee all news

  1. IVERIC bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Kourous A. Rezaei, MD, Chief Medical Officer of IVERIC bio, will present an overview of the Company at the Ladenburg Thalmann 2019 Healthcare Conference in New York on

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2H 2020.
Zimura
Autosomal Recessive Stargardt Disease
Phase 2a top-line data released November 12, 2018 noted that treatment was generally well tolerated.
Zimura
Wet age-related macular degeneration (Wet-AMD)
Phase 3 data released December 12, 2016 - primary endpoint not met. Data from third trial released August 14, 2017- primary endpoint not met.
Fovista
Wet age-related macular degeneration (Wet-AMD)
Phase 2b initial data due 4Q 2019.
Zimura
Geographic atrophy
Phase 1/2 trial to be initiated 1H 2021.
IC-200
BEST1 related retinal diseases
Phase 1/2 trial to be initiated 2H 2020.
IC-100
Rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP)

Latest News

  1. IVERIC bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Kourous A. Rezaei, MD, Chief Medical Officer of IVERIC bio, will present an overview of the Company at the Ladenburg Thalmann 2019 Healthcare Conference in New York on